212 related articles for article (PubMed ID: 30566030)
1. Dalfampridine benefits ambulation but not cognition in multiple sclerosis.
Satchidanand N; Drake A; Smerbeck A; Hojnacki D; Kolb C; Patrick K; Weinstock-Guttman B; Motl R; Benedict RH
Mult Scler; 2020 Jan; 26(1):91-98. PubMed ID: 30566030
[TBL] [Abstract][Full Text] [Related]
2. Dalfampridine effects on cognition, fatigue, and dexterity.
Korsen M; Kunz R; Schminke U; Runge U; Kohlmann T; Dressel A
Brain Behav; 2017 Jan; 7(1):e00559. PubMed ID: 28127507
[TBL] [Abstract][Full Text] [Related]
3. Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial.
Applebee A; Goodman AD; Mayadev AS; Bethoux F; Goldman MD; Klingler M; Blight AR; Carrazana EJ
Clin Ther; 2015 Dec; 37(12):2780-7. PubMed ID: 26565077
[TBL] [Abstract][Full Text] [Related]
4. Effect of dalfampridine on information processing speed impairment in multiple sclerosis.
De Giglio L; De Luca F; Gurreri F; Ferrante I; Prosperini L; Borriello G; Quartuccio E; Gasperini C; Pozzilli C
Neurology; 2019 Aug; 93(8):e733-e746. PubMed ID: 31331968
[TBL] [Abstract][Full Text] [Related]
5. Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.
Limone BL; Sidovar MF; Coleman CI
Health Qual Life Outcomes; 2013 Jun; 11():105. PubMed ID: 23799913
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.
Goodman AD; Bethoux F; Brown TR; Schapiro RT; Cohen R; Marinucci LN; Henney HR; Blight AR;
Mult Scler; 2015 Sep; 21(10):1322-31. PubMed ID: 25583832
[TBL] [Abstract][Full Text] [Related]
7. A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.
Goodman AD; Brown TR; Edwards KR; Krupp LB; Schapiro RT; Cohen R; Marinucci LN; Blight AR;
Ann Neurol; 2010 Oct; 68(4):494-502. PubMed ID: 20976768
[TBL] [Abstract][Full Text] [Related]
8. Dalfampridine extended release: in multiple sclerosis.
Chwieduk CM; Keating GM
CNS Drugs; 2010 Oct; 24(10):883-91. PubMed ID: 20839898
[TBL] [Abstract][Full Text] [Related]
9. Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis.
Dunn J; Blight A
Curr Med Res Opin; 2011 Jul; 27(7):1415-23. PubMed ID: 21595605
[TBL] [Abstract][Full Text] [Related]
10. Dalfampridine: a medication to improve walking in patients with multiple sclerosis.
Pikoulas TE; Fuller MA
Ann Pharmacother; 2012; 46(7-8):1010-5. PubMed ID: 22764324
[TBL] [Abstract][Full Text] [Related]
11. Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis.
Coleman CI; Sobieraj DM; Marinucci LN
Curr Med Res Opin; 2012 Jan; 28(1):49-56. PubMed ID: 22073939
[TBL] [Abstract][Full Text] [Related]
12. Effects of Physical Therapy and Dalfampridine on Function and Quality of Life in Nonambulatory Individuals With Multiple Sclerosis: A Randomized Controlled Trial.
Bromley LE; Weinstock-Guttman B
Int J MS Care; 2024; 26(3):98-103. PubMed ID: 38765304
[TBL] [Abstract][Full Text] [Related]
13. Dalfampridine in multiple sclerosis: from symptomatic treatment to immunomodulation.
Espejo C; Montalban X
Clin Immunol; 2012 Jan; 142(1):84-92. PubMed ID: 21742559
[TBL] [Abstract][Full Text] [Related]
14. Changes in Cognitive Processing Speed, Mood, and Fatigue in an Observational Study of Persons With Multiple Sclerosis Treated With Dalfampridine-ER.
Triche EW; Ruiz JA; Olson KM; Lo AC
Clin Neuropharmacol; 2016; 39(2):73-80. PubMed ID: 26818040
[TBL] [Abstract][Full Text] [Related]
15. Long-term effects of dalfampridine in patients with multiple sclerosis.
Ruck T; Bittner S; Simon OJ; Göbel K; Wiendl H; Schilling M; Meuth SG
J Neurol Sci; 2014 Feb; 337(1-2):18-24. PubMed ID: 24290498
[TBL] [Abstract][Full Text] [Related]
16. Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study.
Cameron MH; Fitzpatrick M; Overs S; Murchison C; Manning J; Whitham R
Mult Scler; 2014 May; 20(6):733-8. PubMed ID: 24099749
[TBL] [Abstract][Full Text] [Related]
17. Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern.
Zörner B; Filli L; Reuter K; Kapitza S; Lörincz L; Sutter T; Weller D; Farkas M; Easthope CS; Czaplinski A; Weller M; Linnebank M
Mult Scler; 2016 Oct; 22(11):1463-1475. PubMed ID: 26762672
[TBL] [Abstract][Full Text] [Related]
18. Predicting responsiveness to fampridine in gait-impaired patients with multiple sclerosis.
Filli L; Werner J; Beyer G; Reuter K; Petersen JA; Weller M; Zörner B; Linnebank M
Eur J Neurol; 2019 Feb; 26(2):281-289. PubMed ID: 30171655
[TBL] [Abstract][Full Text] [Related]
19. Development of dalfampridine, a novel pharmacologic approach for treating walking impairment in multiple sclerosis.
Blight AR; Henney HR; Cohen R
Ann N Y Acad Sci; 2014 Nov; 1329():33-44. PubMed ID: 25154911
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology and clinical efficacy of dalfampridine for treating multiple sclerosis.
Lugaresi A
Expert Opin Drug Metab Toxicol; 2015 Feb; 11(2):295-306. PubMed ID: 25510833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
